Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vivus: into single digits -- Ignore unavailable to you. Want to Upgrade?

To: Tunica Albuginea who wrote (30)	2/4/1998 5:38:00 PM
From: jack w garnes jr.	Read Replies (1) \| Respond to of 1016

TA, Give the man a break. I like to watch Doctors fight. There no quesition about it... you are a smart M.D. I really appriciate your input. Have a good night JG

To: Tunica Albuginea who wrote (30)	2/4/1998 7:00:00 PM
From: Bradpalm1	Read Replies (1) \| Respond to of 1016

Tunica, Your recent response to Dale is one of the most contemptible and laughable posts I've seen in a long time. Who designated you, of all people, arbiter of admissible medical thought and opinion on this or any other thread? I guess Dale wont be on your 'unelected Vivus Editorial Board' anytime soon either <GGGG>. Bradpalm1

To: Tunica Albuginea who wrote (30)	2/4/1998 8:10:00 PM
From: MIKE DUBIS	Read Replies (2) \| Respond to of 1016

Tuna: You should be ashamed of yourself for your post to Dale.

To: Tunica Albuginea who wrote (30)	2/4/1998 11:30:00 PM
From: poodle	Read Replies (3) \| Respond to of 1016

Urology 1997 Nov;50(5):809-811 MUSE therapy: preliminary clinical observations. Werthman P, Rajfer J Department of Urology, University of California at Los Angeles School of Medicine 90095-1738, USA. OBJECTIVES: Intracavernosal injection of vasodilating agents has been a mainstay in the treatment of erectile dysfunction. Recently, a transurethral delivery system (MUSE) for alprostadil (prostaglandin E1) was introduced as an alternative form of pharmacotherapy. METHODS: One hundred consecutive patients with erectile dysfunction were treated with MUSE in doses ranging from 125 to 1000 micrograms and their erections were observed in the clinical setting. All patients had previous intracavernosal injections of combination pharmacotherapy (papavarine, Regitine, and/or prostaglandin E1). RESULTS: Of these 100 patients that used MUSE, only 7% had well-sustained, rigid erections while 30% had full erections but with partial rigidity. The remaining 63% of patients did not achieve erections that they thought were adequate for penetration. Penile and/or perineal pain occurred in 24% of patients, 3% had a syncopal episode, and 3% experienced urethral bleeding. One patient had priapism that required drainage. Using intracavernosal injections, 49% had sustained rigid erections, 40% had full erections with partial rigidity, and 11% did not have a response satisfactory for penetration. CONCLUSIONS: These data suggest that intracavernosal injections appear to be more effective than MUSE in achieving a rigid erection in men with erectile dysfunction. Publication Types: Clinical trial PMID: 9372900, UI: 98040182